Reported Earnings • May 27
Full year 2026 earnings released: EPS: ₹75.01 (vs ₹46.30 in FY 2025) Full year 2026 results: EPS: ₹75.01 (up from ₹46.30 in FY 2025). Revenue: ₹23.0b (up 34% from FY 2025). Net income: ₹1.88b (up 62% from FY 2025). Profit margin: 8.1% (up from 6.7% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Feb 12
Third quarter 2026 earnings released: EPS: ₹13.04 (vs ₹12.34 in 3Q 2025) Third quarter 2026 results: EPS: ₹13.04 (up from ₹12.34 in 3Q 2025). Revenue: ₹6.17b (up 40% from 3Q 2025). Net income: ₹325.9m (up 5.6% from 3Q 2025). Profit margin: 5.3% (down from 7.0% in 3Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Nov 08
Second quarter 2026 earnings released: EPS: ₹21.69 (vs ₹15.37 in 2Q 2025) Second quarter 2026 results: EPS: ₹21.69 (up from ₹15.37 in 2Q 2025). Revenue: ₹5.65b (up 39% from 2Q 2025). Net income: ₹542.2m (up 41% from 2Q 2025). Profit margin: 9.6% (in line with 2Q 2025). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Jul 24
Full year 2025 earnings released: EPS: ₹46.30 (vs ₹64.60 in FY 2024) Full year 2025 results: EPS: ₹46.30 (down from ₹64.60 in FY 2024). Revenue: ₹17.2b (up 33% from FY 2024). Net income: ₹1.16b (down 28% from FY 2024). Profit margin: 6.7% (down from 13% in FY 2024). Post-clinical trial products Approved (during full year): 4 Launched (during full year): 1 Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jul 23
AstraZeneca Pharma India Limited, Annual General Meeting, Aug 14, 2025 AstraZeneca Pharma India Limited, Annual General Meeting, Aug 14, 2025, at 15:00 Indian Standard Time. Declared Dividend • Jul 14
Dividend increased to ₹32.00 Dividend of ₹32.00 is 33% higher than last year. Ex-date: 18th July 2025 Payment date: 1st January 1970 Dividend yield will be 0.3%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (69% earnings payout ratio) but not covered by cash flows (126% cash payout ratio). The dividend has increased by an average of 59% per year over the past 6 years. However, payments have been volatile during that time. Earnings per share has grown by 9.9% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Reported Earnings • May 31
Full year 2025 earnings released: EPS: ₹46.30 (vs ₹64.60 in FY 2024) Full year 2025 results: EPS: ₹46.30 (down from ₹64.60 in FY 2024). Revenue: ₹17.6b (up 36% from FY 2024). Net income: ₹1.16b (down 28% from FY 2024). Profit margin: 6.6% (down from 13% in FY 2024). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth. Announcement • May 21
AstraZeneca Pharma India Limited to Report Q4, 2025 Results on May 30, 2025 AstraZeneca Pharma India Limited announced that they will report Q4, 2025 results on May 30, 2025 Reported Earnings • Feb 12
Third quarter 2025 earnings released: EPS: ₹12.34 (vs ₹6.32 in 3Q 2024) Third quarter 2025 results: EPS: ₹12.34 (up from ₹6.32 in 3Q 2024). Revenue: ₹4.48b (up 47% from 3Q 2024). Net income: ₹308.5m (up 95% from 3Q 2024). Profit margin: 6.9% (up from 5.2% in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Feb 12
AstraZeneca India Reportedly Plans to Sell North Bengaluru Unit for INR 32,000 Million AstraZeneca Pharma India Limited (BSE:506820) plans to sell its 64-acre production facility in North Bengaluru as part of a strategic review of its global manufacturing and supply network conducted by its parent company. The deal is expected to fetch over INR 32,000 million. This move is a part of its broader corporate land monetisation plan. According to property consultants, a global mandate has been issued to select consultants for the land deal. “The land, valued at over INR 500 million per acre, is in one of Bengaluru’s most sought-after corridors and serves as a manufacturing facility for the pharma major. The land was intermittently on the market for resale; however, the quoted price was previously too high,” said one of the property consultants. The company had earlier stated that it intends to position the manufacturing site for sale in a fully operational manner and begin searching for a buyer who can also function as a contract manufacturing organisation (CMO) for its products currently manufactured or packaged at the site, subject to necessary statutory approvals. AstraZeneca Pharma’s facility in Bengaluru is one of nine global sites specialising in designing and conducting clinical trials, as well as monitoring safety, efficacy, and regulatory compliance throughout a product’s lifecycle. Announcement • Jan 20
AstraZeneca Pharma India Limited to Report Q3, 2025 Results on Feb 11, 2025 AstraZeneca Pharma India Limited announced that they will report Q3, 2025 results on Feb 11, 2025 Announcement • Nov 21
AstraZeneca Pharma India Limited Launches Breztri Aerosphere in January 2025 in India AstraZeneca Pharma India Limited announced it will launch Breztri Aerosphere in January 2025 in India. Breztri Aerosphere is indicated for the maintenance treatment to relieve symptoms and prevent exacerbations in adult patients with chronic obstructive pulmonary disease (COPD). Reported Earnings • Nov 14
Second quarter 2025 earnings released: EPS: ₹15.37 (vs ₹20.95 in 2Q 2024) Second quarter 2025 results: EPS: ₹15.37 (down from ₹20.95 in 2Q 2024). Revenue: ₹4.16b (up 34% from 2Q 2024). Net income: ₹384.3m (down 27% from 2Q 2024). Profit margin: 9.2% (down from 17% in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Oct 25
AstraZeneca Pharma India Limited to Report Q2, 2025 Results on Nov 13, 2024 AstraZeneca Pharma India Limited announced that they will report Q2, 2025 results on Nov 13, 2024 Announcement • Sep 25
Astrazeneca Pharma India Limited Announces Executive Changes AstraZeneca Pharma India Limited announced that based on the recommendation of the Nomination & Remuneration Committee meeting, the Board of Directors have appointed Ms. Monica Widhani (DIN: 07674403) as an Additional Director (Independent) on the Board of the Company, with effect from September 25, 2024. Mr. Narayan. K. Seshadri (DIN: 053563), Independent Director of the Company, will retire as Director of the Company upon completion of his term of office, at the close of business hours on September 29, 2024. Ms. Shipla Divekar Nirula, Independent Director has been unanimously elected as Chairperson of the Board. Ms. Monica Widhani is has worked with Bharat Petroleum Corporation Limited (BPCL), India's second largest oil marketing company. During her tenure of over 34 years with BPCL she has held various leadership positions in Aviation, Coordination, Retail Marketing, Retail
Strategy, and Finance. These includes positions of Head of Retail Sales for North India, Head of Urban Retailing Strategy, Executive Director Coordination, and then as SBU Head of Aviation. Ms. Widhani has also held Board positions representing BPCL in its various Aviation Joint Ventures. She is currently also an Independent Director on the Board of ABB India Limited, Gujarat Pipavav Port Limited, HG Engineering Infra Limited, and Dreamfolks Services Limited. Ms. Monica Widhani is a Science Hons. Graduate and a qualified Chartered Accountant. She is the first woman Chartered Accountant in the state of Rajasthan and first woman Business Head for BPCL. New Risk • Sep 25
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (351% cash payout ratio). Share price has been volatile over the past 3 months (7.9% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (6.9% net profit margin). Announcement • Aug 10
AstraZeneca Pharma India Limited Approves Dividend for the Financial Year 2023-2024 AstraZeneca Pharma India Limited announced that at the AGM held on August 8, 2024 approved dividend of INR 24 per share on equity shares for the financial year 2023-2024. New Risk • Aug 09
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 6.9% Last year net profit margin: 12% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (351% cash payout ratio). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (6.9% net profit margin). Announcement • Jul 24
AstraZeneca Pharma India Limited to Report Q1, 2025 Results on Aug 08, 2024 AstraZeneca Pharma India Limited announced that they will report Q1, 2025 results on Aug 08, 2024 Announcement • Jul 18
AstraZeneca Pharma India Limited, Annual General Meeting, Aug 08, 2024 AstraZeneca Pharma India Limited, Annual General Meeting, Aug 08, 2024, at 15:00 Indian Standard Time. Reported Earnings • Jul 18
Full year 2024 earnings released: EPS: ₹64.60 (vs ₹39.72 in FY 2023) Full year 2024 results: EPS: ₹64.60 (up from ₹39.72 in FY 2023). Revenue: ₹13.0b (up 29% from FY 2023). Net income: ₹1.62b (up 63% from FY 2023). Profit margin: 13% (up from 9.9% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth. Announcement • Jul 04
Astrazeneca Pharma India Limited Appoints Srikanth B.S. as Site Lead, India Operations, Effective August 1, 2024 AstraZeneca Pharma India Limited have approved the appointment of Mr. Srikanth B.S. as Site Lead, India Operations with effect from August 1, 2024. Mr. Srikanth is an Industrial engineer with master's diploma in Business administration with over 27 years of experience. He has wealth of experience from companies like Dr. Reddy's and GE. He has served AstraZeneca for over 23 years and has worked in multiple functions with experience in areas of procurement, production, planning, product outsourcing, Distribution, new product introduction and ERP implementation with thorough understanding of the concepts of integrated supply chain. He has led and transformed the supply chain function to ensure timely supplies with zero stock outs, led successful CFA optimization projects across distribution network and improved compliance across the entire supply chain and has also managed multiple product switches from AstraZeneca global sites into India operations. Declared Dividend • Jun 27
Dividend increased to ₹24.00 Dividend of ₹24.00 is 50% higher than last year. Ex-date: 5th July 2024 Payment date: 6th September 2024 Dividend yield will be 0.4%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (37% earnings payout ratio) but not covered by cash flows (351% cash payout ratio). The dividend has increased by an average of 64% per year over the past 5 years. However, payments have been volatile during that time. Earnings per share has grown by 24% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Reported Earnings • May 28
Full year 2024 earnings released: EPS: ₹64.80 (vs ₹39.72 in FY 2023) Full year 2024 results: EPS: ₹64.80 (up from ₹39.72 in FY 2023). Revenue: ₹13.3b (up 33% from FY 2023). Net income: ₹1.62b (up 63% from FY 2023). Profit margin: 12% (up from 9.9% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth. Announcement • May 17
AstraZeneca Pharma India Limited to Report Q4, 2024 Results on May 27, 2024 AstraZeneca Pharma India Limited announced that they will report Q4, 2024 results on May 27, 2024 Announcement • Feb 20
Astrazeneca Pharma India Limited Announces Board Changes AstraZeneca Pharma India Limited announced that Mr. Amit Bhakri, currently the Business Unit Director - Biopharmaceutical Business Unit. He will be transitioning from the said role with effect from close of business hours on March 31, 2024, as he takes up another responsibility within AstraZeneca group. Further, Company announced that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved the appointment of Mr. Ayush Kumar Agarwal as Business Unit Director- Biopharmaceutical Business Unit with effect from April 1, 2024. Currently he is the Director - Commercial excellence and will continue leading the same in the interim untill a replacement for the said position is filled. Mr. Ayush Kumar Agarwal is a PostGraduate in Marketing Management with over 28 years of rich industry experience. He has been with AstraZeneca since 2004 when he joined in India as Area Business Manager - Specialty Care. Over last 16 years, he has held multiple sales, marketing, and leadership positions in AstraZeneca. Under Ayush's leadership, Fasenra has grown by 111% and Forxiga by 52% in public channel in 2023. He has guided SFE team in simplifying and automating dashboards. He has paved way for multiple new launches and line extensions in the country like Enhertu, Koselugo and many more bringing India MC closer to reaching the Bold Ambition 2025. He has held some critical positions during his stint with AstraZeneca such as - Director Frontier Markets, Asia Area Chief of Staff, Interim Asia Area Commercial Director - BBU. Currently, he is the Director Commercial Excellence. Reported Earnings • Feb 10
Third quarter 2024 earnings released: EPS: ₹6.32 (vs ₹11.72 in 3Q 2023) Third quarter 2024 results: EPS: ₹6.32 (down from ₹11.72 in 3Q 2023). Revenue: ₹3.15b (up 26% from 3Q 2023). Net income: ₹158.0m (down 46% from 3Q 2023). Profit margin: 5.0% (down from 12% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. New Risk • Feb 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (85% accrual ratio). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.2% average weekly change). Announcement • Feb 08
AstraZeneca Pharma India Limited Announces Board Changes AstraZeneca Pharma India Limited announced that the board of directors have appointed Ms. Bhavana Agrawal as an Additional Director and a Whole-time Director on the Board of the Company, with effect from February 8, 2024. She will take up this responsibility in addition to the duties of being the Chief Financial Officer at AstraZeneca Pharma India Limited. Further, the company informed that Ms. Weiying Sarah Wang, Non-Executive Director has resigned from the office of Director of AstraZeneca Pharma India Limited with effect from close of working hours on February 8, 2024 due to changes in her role and responsibilities that she will continue to pursue within AstraZeneca. While taking note of the same, the Board has placed on record its sincere thanks and appreciation for her contribution during her tenure in the company. Ms. Bhavana Agrawal is currently the Chief Financial Officer of AstraZeneca Pharma India Limited. She comes with over two decades of finance experience and has worked across multiple geographies & businesses. She played various roles with GE prior to joining AZ and her last responsibility was based out of Dubai as a CFO Services business at GE Healthcare for Middle East, Africa & Russia where she provided Finance leadership to $300 million revenue business across 30+ countries. With her expertise around Commercial Finance, P&L Management, financial planning /Analysis, Cash flow management, Accounting & Controls, she was a strategic finance partner for businesses with consistent performance in maximising revenue, margin & cash. She carries strong leadership with proven record in creating positive team culture & growth. Prior to CFO role, she had performed multiple roles across finance domain between 2003 to 2015 in Dubai and India for GE. Bhavana Agrawal is an AllIndia rank holder as a Chartered Accountant. Earlier she completed her Bachelor of Business Studies in Delhi University. Announcement • Jan 26
AstraZeneca Pharma India Limited to Report Q3, 2024 Results on Feb 08, 2024 AstraZeneca Pharma India Limited announced that they will report Q3, 2024 results on Feb 08, 2024 Board Change • Nov 15
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Nirula Shilpa Divekar was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Nov 10
Astrazeneca Pharma India Limited Appoints Hooi-Bien Chuah as Additional Director (Non-Executive) AstraZeneca Pharma India Limited announced that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved the appointment of Ms. Hooi-Bien Chuah (DIN: 10381891), as an Additional Director (Non-Executive) of the Company with effect from November 9, 2023. Ms. Hooi Bien is Asia Area Legal Director for AstraZeneca since April 2021. She has over two decades of legal experience spanning across pharmaceutical, consumer health, technology, and oil & gas industries. Prior to AstraZeneca, she was with Lazada, an e- commerce marketplace platform and logistics company under the Alibaba Group, as SVP Head of Legal (Malaysia) and Litigation Centre of Excellence lead (Southeast Asia). Hooi Bien was also the Legal Director and Ethics & Compliance Officer for GSK Malaysia & Brunei, and had served Shell Malaysia and UCB Asia Pacific in legal and company secretary roles, after starting out her career in private practice with Messrs. K.B. Chua & Co in 1998. Hooi Bien holds an MBA from the University of Strathclyde and an LLB (Honours) from the University of Leicester, and was called to the English Bar and Malaysian Bar in 1997 and 1998 respectively. She also held a Leading Professional in Ethics & Compliance certification. In recognition of various achievements, Hooi Bien and her teams had received multiple Asian Legal Business awards, including In-House Lawyer of the Year 2016 (Southeast Asia), Pharmaceutical & Healthcare Team of the Year 2022 (Southeast Asia), Technology, Media & Telecommunications Team of the Year 2021 (Malaysia) and Innovative Team of the Year 2020 (Malaysia). Announcement • Oct 31
AstraZeneca Pharma India Limited to Report Q3, 2024 Results on Nov 09, 2023 AstraZeneca Pharma India Limited announced that they will report Q3, 2024 results on Nov 09, 2023 Announcement • Sep 15
AstraZeneca Pharma India Limited Appoints Praveen Akkinepally as the Business Unit Head Oncology with Effect from November 1, 2023 AstraZeneca Pharma India Limited announced that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company has approved the appointment of Mr. Praveen Akkinepally as the Business Unit Head Oncology with effect from November 1, 2023. Mr. Praveen will be part of the Senior Management team of the Company. Mr. Praveen Akkinepally holds an MBA from The University of Michigan, Ross School of Business and an Master in Public Health from Johns Hopkins University, Bloomberg School of Public Health. He has been recognized by Diversity MBA Magazine in their annual Top 100 Under 50 list of Executive and Emerging Leaders. Currently, Mr. Praveen Akkinepally is the Head of Lung Cancer Commercialization, AstraZeneca Gaithersburg, MD, USA. Announcement • Aug 18
AstraZeneca Pharma India Limited Approves Dividend for the Financial Year 2022-2023 AstraZeneca Pharma India Limited announced that at the AGM held on August 14, 2023 approved dividend of INR 16 per share on equity shares for the financial year 2022-2023. Announcement • Aug 05
AstraZeneca Pharma India Limited to Report Q1, 2024 Results on Aug 14, 2023 AstraZeneca Pharma India Limited announced that they will report Q1, 2024 results on Aug 14, 2023 Announcement • Aug 01
AstraZeneca Pharma India Limited Announces Executive Changes AstraZeneca Pharma India Limited informed on the change in role of Mr. Atul Tandon, Business Unit Head – Oncology. He will be transitioning from the said role with effect from close of business hours on July 31, 2023, as he takes up another responsibility within AstraZeneca group. In the interim, the Oncology Business Unit of the Company will be managed by Mr. Ayush Kumar Agarwal, who is currently the Director - Commercial Excellence. Reported Earnings • Jul 26
Full year 2023 earnings released: EPS: ₹39.72 (vs ₹24.64 in FY 2022) Full year 2023 results: EPS: ₹39.72 (up from ₹24.64 in FY 2022). Revenue: ₹10.0b (up 25% from FY 2022). Net income: ₹992.9m (up 61% from FY 2022). Profit margin: 9.9% (up from 7.6% in FY 2022). Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 4% per year. Upcoming Dividend • Jul 07
Upcoming dividend of ₹16.00 per share at 0.4% yield Eligible shareholders must have bought the stock before 14 July 2023. Payment date: 13 September 2023. Payout ratio is a comfortable 40% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (1.0%). Reported Earnings • Jun 03
Full year 2023 earnings released: EPS: ₹39.72 (vs ₹24.64 in FY 2022) Full year 2023 results: EPS: ₹39.72 (up from ₹24.64 in FY 2022). Revenue: ₹10.3b (up 28% from FY 2022). Net income: ₹992.9m (up 61% from FY 2022). Profit margin: 9.6% (up from 7.6% in FY 2022). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Announcement • May 23
AstraZeneca Pharma India Limited to Report Q4, 2023 Results on May 30, 2023 AstraZeneca Pharma India Limited announced that they will report Q4, 2023 results on May 30, 2023 Reported Earnings • Feb 16
Third quarter 2023 earnings released: EPS: ₹11.72 (vs ₹4.57 in 3Q 2022) Third quarter 2023 results: EPS: ₹11.72 (up from ₹4.57 in 3Q 2022). Revenue: ₹2.57b (up 28% from 3Q 2022). Net income: ₹293.0m (up 157% from 3Q 2022). Profit margin: 11% (up from 5.7% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 6% per year. Announcement • Jan 31
AstraZeneca Pharma India Limited to Report Q3, 2023 Results on Feb 10, 2023 AstraZeneca Pharma India Limited announced that they will report Q3, 2023 results on Feb 10, 2023 Board Change • Jan 12
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Nirula Shilpa Divekar was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 16
Second quarter 2023 earnings released: EPS: ₹13.03 (vs ₹4.78 in 2Q 2022) Second quarter 2023 results: EPS: ₹13.03 (up from ₹4.78 in 2Q 2022). Revenue: ₹2.36b (up 19% from 2Q 2022). Net income: ₹325.6m (up 173% from 2Q 2022). Profit margin: 14% (up from 6.0% in 2Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 8% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Nirula Shilpa Divekar was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 13
Second quarter 2023 earnings released: EPS: ₹13.03 (vs ₹4.78 in 2Q 2022) Second quarter 2023 results: EPS: ₹13.03 (up from ₹4.78 in 2Q 2022). Revenue: ₹2.43b (up 21% from 2Q 2022). Net income: ₹325.6m (up 173% from 2Q 2022). Profit margin: 13% (up from 6.0% in 2Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 10% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Jul 17
Full year 2022 earnings released: EPS: ₹24.64 (vs ₹37.32 in FY 2021) Full year 2022 results: EPS: ₹24.64 (down from ₹37.32 in FY 2021). Revenue: ₹8.06b (down 1.0% from FY 2021). Net income: ₹616.0m (down 34% from FY 2021). Profit margin: 7.6% (down from 12% in FY 2021). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Jun 30
Upcoming dividend of ₹8.00 per share Eligible shareholders must have bought the stock before 07 July 2022. Payment date: 06 September 2022. Payout ratio is a comfortable 32% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.8%). Lower than average of industry peers (1.0%). Reported Earnings • May 28
Full year 2022 earnings released: EPS: ₹24.84 (vs ₹37.32 in FY 2021) Full year 2022 results: EPS: ₹24.84 (down from ₹37.32 in FY 2021). Revenue: ₹8.20b (flat on FY 2021). Net income: ₹615.9m (down 34% from FY 2021). Profit margin: 7.5% (down from 12% in FY 2021). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 14% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Additional Non-Executive Independent Director Nirula Shilpa Divekar was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 09
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹4.57 (down from ₹8.42 in 3Q 2021). Revenue: ₹2.06b (up 2.8% from 3Q 2021). Net income: ₹114.2m (down 46% from 3Q 2021). Profit margin: 5.5% (down from 11% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 16% per year. Board Change • Feb 09
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Additional Non-Executive Independent Director Nirula Shilpa Divekar was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Jul 18
Full year 2021 earnings released: EPS ₹37.32 (vs ₹28.88 in FY 2020) The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2021 results: Revenue: ₹8.14b (down 2.2% from FY 2020). Net income: ₹933.0m (up 29% from FY 2020). Profit margin: 12% (up from 8.7% in FY 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 39% per year whereas the company’s share price has increased by 35% per year. Reported Earnings • May 30
Full year 2021 earnings released: EPS ₹37.32 (vs ₹28.88 in FY 2020) The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2021 results: Revenue: ₹8.14b (down 2.2% from FY 2020). Net income: ₹933.0m (up 29% from FY 2020). Profit margin: 12% (up from 8.7% in FY 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth. Executive Departure • Mar 25
Executive VP, President of Research & Development Oncology Jose Baselga has left the company On the 21st of March, Jose Baselga's tenure as Executive VP, President of Research & Development Oncology ended after 2.2 years in the role. We don't have any record of a personal shareholding under Jose's name. A total of 2 executives have left over the last 12 months. Is New 90 Day High Low • Feb 23
New 90-day low: ₹3,458 The company is down 23% from its price of ₹4,512 on 25 November 2020. The Indian market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period. Is New 90 Day High Low • Jan 18
New 90-day low: ₹4,026 The company is down 7.0% from its price of ₹4,314 on 20 October 2020. The Indian market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 11% over the same period. Is New 90 Day High Low • Dec 07
New 90-day high: ₹4,608 The company is up 9.0% from its price of ₹4,231 on 08 September 2020. The Indian market is up 16% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Pharmaceuticals industry, which is also up 9.0% over the same period. Reported Earnings • Nov 07
Second quarter 2021 earnings released: EPS ₹10.54 The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₹2.14b (up 2.7% from 2Q 2020). Net income: ₹263.4m (up 83% from 2Q 2020). Profit margin: 12% (up from 6.9% in 2Q 2020). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth. 
